Clinical Trial Update: Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial studying onabotulinumtoxinA and galcanezumab for migraine has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Galcanezumab (galcanezumab)
• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Diamond Headache Clinic | Conditions: Migraine | Phase 4 | Status: TERMINATED